Transcatheter pulmonary valve insertion: when, how, and why

2012 ◽  
Vol 22 (6) ◽  
pp. 696-701 ◽  
Author(s):  
Jeremy M. Ringewald ◽  
Elsa J. Suh
Keyword(s):  
Valve Replacement ◽  
Pulmonary Valve ◽  
Pulmonary Valve Replacement ◽  
Percutaneous Approach ◽  
Transcatheter Pulmonary Valve Replacement ◽  
Late Morbidity ◽  
Complementary Strategy ◽  
Term Management

AbstractTranscatheter pulmonary valve replacement is fast becoming an accepted alternative to repeat surgical pulmonary valve replacement for selected patients and therefore a complementary strategy in the long-term management of those requiring surgical pulmonary valve replacement. With a combined surgical and percutaneous approach, late morbidity for some of these patients may be diminished. This manuscript will review the current indications for this procedure, its limitations, and its benefits.

Transcatheter pulmonary valve insertion, expanded use and future directions

2013 ◽  
Vol 23 (6) ◽  
pp. 910-914 ◽  
Author(s):  
Jeremy M. Ringewald ◽  
Elsa J. Suh
Keyword(s):  
Congenital Heart ◽  
Pulmonary Valve ◽  
Pulmonary Valve Replacement ◽  
Future Directions ◽  
Percutaneous Approach ◽  
Transcatheter Pulmonary Valve Replacement ◽  
Late Morbidity ◽  
Complementary Strategy ◽  
Term Management

AbstractTranscatheter pulmonary valve replacement with the Melody® valve is an accepted alternative to surgical replacement of the pulmonary valve for some patients and therefore a complementary strategy in the long-term management of several groups of patients with congenital heart disease. It allows at least extending the time between sternotomies and possibly improving late outcomes. With a combined surgical and percutaneous approach, late morbidity for some of these patients will likely be diminished. This manuscript will review the current expanded applications for this technology, demonstrate several examples of its use and discuss future directions for this evolving equipment.

Transcatheter Pulmonary Valve Replacement in Patients With Congenital Heart Disease

2018 ◽  
Vol 38 (1) ◽  
pp. 30-36
Author(s):  
Shantelle Bartra
Keyword(s):  
Valve Replacement ◽  
Pulmonary Valve ◽  
Insertion Site ◽  
Pulmonary Valve Replacement ◽  
Long Term Outcomes ◽  
Transcatheter Pulmonary Valve Replacement ◽  
Feasible Alternative ◽  
Short And Long Term ◽  
Infection Monitoring

Transcatheter pulmonary valve replacement is now a feasible alternative to surgical pulmonary valve replacement in children and adults with dysfunctional right ventricular outflow conduits. Currently, 2 types of valves can be used for this application. This article provides an overview of the procedure and how it is performed, indications and contraindications for transcatheter pulmonary valve replacement, and short- and long-term outcomes. Nursing considerations mainly focus on educating patients, preventing bleeding and infection, monitoring renal function, and preventing injury to the catheter insertion site. This article enhances the knowledge of nurses working in cardiac catheterization laboratories and post-procedure recovery and cardiac units so that the nurses can anticipate interventions and understand the management of patients who have transcatheter pulmonary valve replacement.

scholarly journals Mid- to long-term follow-up of pulmonary valve replacement with BioIntegral injectable valve

2020 ◽  
Author(s):  
Simone Ghiselli ◽  
Cristina Carro ◽  
Nicola Uricchio ◽  
Giuseppe Annoni ◽  
Stefano M Marianeschi
Keyword(s):  
Cardiopulmonary Bypass ◽  
Right Ventricular ◽  
Tetralogy Of Fallot ◽  
Valve Replacement ◽  
Pulmonary Valve ◽  
Pulmonary Stenosis ◽  
Pulmonary Regurgitation ◽  
Pulmonary Valve Replacement

Abstract OBJECTIVES Chronic pulmonary valve (PV) regurgitation is a common late sequela after repair of congenital heart diseases like tetralogy of Fallot or pulmonary stenosis, leading to right ventricular dilatation and failure and increased late morbidity and mortality. Timely reoperation may lead to a complete right ventricular recovery. An injectable PV allows pulmonary valve replacement, with or without cardiopulmonary bypass, under direct observation, thereby minimizing the impact of surgery on cardiac function. The aim of this study was to evaluate the feasibility and mid- to long-term clinical outcomes with this device. METHODS From April 2007 to October 2019, a total of 85 symptomatic patients with severe pulmonary regurgitation or pulmonary stenosis underwent pulmonary valve replacement with an injectable stented pulmonary prosthesis. Data were collected from the international proctoring registry. Mean patient age was 26.7 years. The underlying diagnosis was repaired tetralogy of Fallot in 69.4% patients; moderate or severe pulmonary regurgitation was present in 72.9%. All patients had echocardiographic scans before the operation and during the follow-up period. A total of 54.1% patients also had preoperative/postoperative cardiac magnetic resonance imaging (MRI) or catheterization; 25.9% had off-pump implants. In 53% patients, pulmonary valve replacement was associated with the repair of other cardiac defects. RESULTS Minor postoperative complications were observed in 10.8% patients. The overall mortality rate was 2.3%; mortality after valve replacement was linked to a severe cardiac insufficiency and it was not related to a prosthesis failure; 1 prosthesis was explanted from 1 patient because of endocarditis, and 6% of patients developed PV stenosis; minor complications occurred in 4.8%. The mean follow-up period was 4.8 years (2 months–12.7 years); 42% of the patients were followed for more than 5 years. Follow-up echocardiography and cardiac MRI showed a significant reduction in RV size and low gradients across the PV. CONCLUSIONS An injectable PV may be implanted without cardiopulmonary bypass and in a hybrid operating theatre with minimal surgical impact. The bioprosthesis, available up to large sizes, has a low profile, laminar flow and no risk of coronary artery compression. Incidence of endocarditis is rare. The lack of a suture ring permits the implant of a relatively larger prosthesis, thereby avoiding a right ventricular outflow tract obstruction. This device permits future percutaneous valve-in-valve procedures, if needed. Results concerning durability are encouraging, and mid- to long-term haemodynamic performance is excellent.

scholarly journals Infective Endocarditis After Transcatheter Pulmonary Valve Replacement Using the Melody Valve

2013 ◽  
Vol 6 (3) ◽  
pp. 292-300 ◽  
Author(s):  
Doff B. McElhinney ◽  
Lee N. Benson ◽  
Andreas Eicken ◽  
Jacqueline Kreutzer ◽  
Robert F. Padera ◽  
...  
Keyword(s):  
Infective Endocarditis ◽  
Valve Replacement ◽  
Pulmonary Valve ◽  
Pulmonary Valve Replacement ◽  
Melody Valve ◽  
Transcatheter Pulmonary Valve Replacement

Hypoattenuated Leaflet Thickening After Transcatheter Pulmonary Valve Replacement With the SAPIEN 3 Valve

2021 ◽  
Author(s):  
Muhammad Hammadah ◽  
B. Kelly Han ◽  
Mariana de Oliveira Nunes ◽  
Jamil A. Aboulhosn ◽  
Evan M. Zahn ◽  
...  
Keyword(s):  
Valve Replacement ◽  
Pulmonary Valve ◽  
Pulmonary Valve Replacement ◽  
Transcatheter Pulmonary Valve Replacement ◽  
Sapien 3

Reintervention and Survival After Transcatheter Pulmonary Valve Replacement

2022 ◽  
Vol 79 (1) ◽  
pp. 18-32 ◽  
Author(s):  
Doff B. McElhinney ◽  
Yulin Zhang ◽  
Daniel S. Levi ◽  
Stanimir Georgiev ◽  
Elżbieta Katarzyna Biernacka ◽  
...  
Keyword(s):  
Valve Replacement ◽  
Pulmonary Valve ◽  
Pulmonary Valve Replacement ◽  
Transcatheter Pulmonary Valve Replacement

Transcatheter Pulmonary Valve Replacement: Current State of Art

2018 ◽  
Vol 20 (4) ◽  
Author(s):  
Wail Alkashkari ◽  
Amani Alsubei ◽  
Ziyad M. Hijazi
Keyword(s):  
Valve Replacement ◽  
Pulmonary Valve ◽  
Pulmonary Valve Replacement ◽  
Current State ◽  
Transcatheter Pulmonary Valve Replacement ◽  
State Of Art
Sign in / Sign up

Export Citation Format

Share Document